Bone marrow aspirate concentrate, or BMAC, is still an evolving treatment—but the clinical improvements reported by many patients are giving researchers good reasons to keep studying it.
What randomized studies are finding
A 2024 systematic review examined eight randomized studies with 937 patients. Across the studies, people receiving BMAC experienced significant improvement in pain and function beginning about one month after treatment. At six and twelve months, pain results favored BMAC over hyaluronic acid, although the difference was not large enough to clearly exceed the threshold for a clinically important advantage.
That nuance matters. BMAC did not prove superior to every other injection, but it did produce meaningful improvement from baseline without a signal of more serious adverse events.
What improvement can mean
For a patient, a successful result may be returning to nine holes of golf, taking the stairs with greater confidence, walking the dog farther, or delaying a more invasive decision while remaining active.
A prospective study following people with moderate knee arthritis for two years also reported improvements in pain, function, and satisfaction. These results do not prove that BMAC regrows cartilage, but they do show why patients and clinicians remain interested.
Who may be positioned for a better result?
Early and moderate arthritis generally offers more opportunity than a joint with severe deformity. A careful examination, weight-bearing X-rays, realistic goals, and a rehabilitation plan help identify patients most likely to benefit.
The encouraging bottom line
BMAC is not a miracle and remains a self-pay option in many settings. Yet “still being studied” does not mean “nothing positive is happening.” Randomized trials show that many patients improve, sometimes for a year or longer. The next generation of research should clarify who benefits most and whether BMAC offers enough added value over simpler options.
Sources and further reading
This article is educational and is not medical advice.
